Antimullerian hormone levels are lower in BRCA2 mutation carriers.

ABSTRACT:

Objective

To compare antimüllerian hormone (AMH) levels in women at high risk for hereditary breast and ovarian cancer compared with healthy low-risk control women.

Design

Prospective cohort.

Setting

Not applicable.

Patient(s)

Reproductive-age women with a uterus and both ovaries were analyzed in four groups: BRCA1 mutation carriers, BRCA2 carriers, BRCA-negative women, and low-risk controls.

Intervention(s)

Self-collected dried blood spot.

Main outcome measure(s)

AMH levels.

Result(s)

One hundred ninety-five women were included: 55 BRCA1 carriers, 50 BRCA2 carriers, 26 BRCA negative women, and 64 low-risk controls. After adjusting for confounders, BRCA2 carriers had AMH levels that were 33% lower than control women and an increased odds of

SUBMITTER: Johnson L 

PROVIDER: S-EPMC5531590 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature